As of April 22, 2026, Voyager Therapeutics's top three insider holders are Biosciences Inc Neurocrine (TenPercentOwner, 8.58Mn shares), Capital, Llc Ecor1 (TenPercentOwner, 3.85Mn shares), Rock Ventures Iii, L.P. Third (TenPercentOwner, 3.19Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Biosciences Inc Neurocrine | - | 8,575,316 | 0 | 24 Feb, 2022 |
| Capital, Llc Ecor1 | - | 0 | 3,851,507 | 11 Jan, 2023 |
| Rock Ventures Iii, L.P. Third | - | 3,185,291 | 0 | 06 Feb, 2023 |
| Alfred Sandrock | President And Ceo | 472,549 | 0 | 03 Apr, 2026 |
| Robin Swartz | Coo Cbo | 199,738 | 0 | 26 Feb, 2026 |
| Toby Ferguson | Chief Medical Officer | 183,914 | 0 | 10 Feb, 2026 |
| Peter P. Pfreundschuh | Chief Financial Officer | 175,669 | 0 | 22 Feb, 2024 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | 0 | 26 Feb, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | 145,718 | 0 | 26 Feb, 2026 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | 0 | 24 Feb, 2025 |
| Robert W. Hesslein | Senior Vp General Counsel | 102,200 | 0 | 22 Mar, 2023 |
| Julie Burek | Vp, Finance | 52,458 | 0 | 23 Mar, 2022 |
| Gregory L. Shiferman | Svp And General Counsel | 50,000 | 0 | 03 Apr, 2026 |
| Michael J Higgins | Interim President Ceo | 31,314 | 0 | 18 Jul, 2022 |
| Glenn Pierce | Interim Cso | 16,788 | 0 | 18 Jul, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Apr, 2026 | Alfred Sandrock | Common Stock | D | 11,511 | $3.87 | 472,549 | D | S |
| 01 Apr, 2026 | Gregory L. Shiferman | Common Stock | A | 50,000 | $0.00 | 50,000 | D | A |
| 24 Feb, 2026 | Robin Swartz | Common Stock | D | 6,458 | $3.77 | 199,738 | D | S |
| 24 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 4,174 | $3.76 | 145,718 | D | S |
| 24 Feb, 2026 | Nathan D. Jorgensen | Common Stock | D | 4,668 | $3.77 | 151,416 | D | S |
| 24 Feb, 2026 | Alfred Sandrock | Common Stock | D | 14,197 | $3.79 | 484,060 | D | S |
| 18 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,301 | $3.44 | 149,892 | D | S |
| 18 Feb, 2026 | Robin Swartz | Common Stock | D | 3,882 | $3.44 | 206,196 | D | S |
| 18 Feb, 2026 | Alfred Sandrock | Common Stock | D | 11,732 | $3.41 | 498,257 | D | S |
| 10 Feb, 2026 | Alfred Sandrock | Common Stock | D | 12,192 | $3.78 | 509,989 | D | S |
| 10 Feb, 2026 | Robin Swartz | Common Stock | D | 4,569 | $3.85 | 210,078 | D | S |
| 10 Feb, 2026 | Todd Alfred Carter | Common Stock | D | 3,525 | $3.85 | 153,193 | D | S |
| 06 Feb, 2026 | Alfred Sandrock | Common Stock | A | 86,250 | $0.00 | 522,181 | D | A |
| 06 Feb, 2026 | Robin Swartz | Common Stock | A | 45,000 | $0.00 | 214,647 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Common Stock | A | 32,250 | $0.00 | 156,084 | D | A |
| 06 Feb, 2026 | Todd Alfred Carter | Common Stock | A | 33,000 | $0.00 | 156,718 | D | A |
| 06 Feb, 2026 | Toby Ferguson | Common Stock | A | 45,000 | $0.00 | 183,914 | D | A |
| 06 Feb, 2026 | Alfred Sandrock | Stock Option (Right to Buy) | A | 402,500 | $0.00 | 402,500 | D | A |
| 06 Feb, 2026 | Nathan D. Jorgensen | Stock Option (Right to Buy) | A | 150,500 | $0.00 | 150,500 | D | A |
| 06 Feb, 2026 | Robin Swartz | Stock Option (Right to Buy) | A | 210,000 | $0.00 | 210,000 | D | A |